The histone deacetylase inhibitor LBH589 inhibit undifferentiated pleomorphic sarcoma growth via downregulation of FOSL1

被引：0
|
作者：
Saitoh, Yoshinobu [1 ]
Setoguchi, Takao [1 ]
Nagano, Satoshi [1 ]
Taniguchi, Noboru [1 ]
机构：
[1] Kagoshima Univ, Dept Orthop Surg, Kagoshima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3419
引用
收藏
页码：1416 / 1416
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
  • [42] A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Giles, Francis
    Fischer, Thomas
    Cortes, Jorge
    Garcia-Manero, Guillermo
    Beck, Joachim
    Ravandi, Farhad
    Masson, Eric
    Rae, Patricia
    Laird, Glen
    Sharma, Sunil
    Kantarjian, Hagop
    Dugan, Margaret
    Albitar, Maher
    Bhalla, Kapil
    CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4628 - 4635
  • [43] c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589
    Kauh, John
    Fan, Songqing
    Xia, Mingjing
    Yue, Ping
    Yang, Lily
    Khuri, Fadlo R.
    Sun, Shi-Yong
    PLOS ONE, 2010, 5 (04):
  • [44] The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
    Scuto, Anna
    Kirschbaum, Mark
    Kowolik, Claudia
    Kretzner, Leo
    Juhasz, Agnes
    Atadja, Peter
    Pullarkat, Vinod
    Bhatia, Ravi
    Forman, Stephen
    Yen, Yun
    Jove, Richard
    BLOOD, 2008, 111 (10) : 5093 - 5100
  • [45] Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
    Hamberg, Paul
    Woo, Margaret M.
    Chen, Lin-Chi
    Verweij, Jaap
    Porro, Maria Grazia
    Zhao, Lily
    Li, Wenkui
    van der Biessen, Diane
    Sharma, Sunil
    Hengelage, Thomas
    de Jonge, Maja
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 805 - 813
  • [46] Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
    Paul Hamberg
    Margaret M. Woo
    Lin-Chi Chen
    Jaap Verweij
    Maria Grazia Porro
    Lily Zhao
    Wenkui Li
    Diane van der Biessen
    Sunil Sharma
    Thomas Hengelage
    Maja de Jonge
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 805 - 813
  • [47] MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo
    Ye, Ping
    Zhao, Liang
    McGirr, Crystal
    Gonda, Thomas J.
    CANCER LETTERS, 2014, 343 (01) : 98 - 106
  • [48] The histone deacetylase inhibitor LBH589 sensitizes pancreatic cancer cells to TRAIL-induced apoptosis through induction of c-FLIP degradation
    Kauh, John
    Fan, Songqing
    Yang, Lily
    Khuri, Fadlo R.
    Sun, Shi-Yong
    CANCER RESEARCH, 2010, 70
  • [49] Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro
    Chao, Hongtu
    Wang, Li
    Hao, Jingli
    Ni, Jie
    Chang, Lei
    Graham, Peter H.
    Kearsley, John H.
    Li, Yong
    CANCER LETTERS, 2013, 329 (01) : 17 - 26
  • [50] Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
    Ramakrishnan, Vijay
    Kimlinger, Teresa
    Timm, Michael
    Haug, Jessica
    Rajkumar, Vincent
    Kumar, Shaji
    LEUKEMIA RESEARCH, 2014, 38 (11) : 1358 - 1366
12345